PainTEQ has announced the commercial launch of TRAQ, an implant developed for posterior sacroiliac (SI) joint fusion, in the US.
The launch brings a new option for interventionalists and surgeons, as TRAQ becomes an addition to PainTEQ’s existing portfolio alongside the LINQ system, both accessible through the same surgical approach.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TRAQ aims to stabilise the SI joint by allowing bi-cortical fixation; its triangular piercing barbs are intended to engage both the sacral and iliac cortices.
The implant is introduced via a posterior approach using a 1in incision, with a pre-filled graft window placed at the interface to encourage bony incorporation.
PainTEQ research and development vice-president Dwayne Polzer said: “TRAQ’s triangular piercing barbs were an intentional design choice. They engage both the sacral and iliac cortices, which is what this joint needs to stabilise.”
PainTEQ CEO Shanth Thiyagalingam said: “The launch of TRAQ represents the next evolution of our posterior SI joint fusion platform. PainTEQ helped pioneer posterior SI joint fusion with LINQ, and TRAQ builds on that foundation with a new implant designed to further expand physician treatment options while we continue generating high-quality clinical evidence.”
The Spine and Nerve Center of the Virginias CEO and American Society of Pain and Neuroscience founder Timothy Deer performed the first procedure using TRAQ.
To gather additional clinical data, PainTEQ has launched the TRAQTION study. This prospective, multi-centre, post-market trial will assess the safety and efficacy of TRAQ under real-world use.
The study has obtained central institutional review board (IRB) approval from WCG IRB, with plans to enrol up to 100 subjects at ten locations in the US and follow participants for up to 24 months.
PainTEQ operates from Tampa, Florida, and develops medical devices for posterior sacroiliac joint fusion. Its product portfolio features the LINQ and TRAQ implant systems.
In December 2024, PainTEQ received a new US patent for its LinQ SI joint stabilisation system aimed at alleviating SI joint pain.
